Biofourmis’ Post

View organization page for Biofourmis, graphic

36,259 followers

Despite pharma’s emphasis on diversity in clinical trials, many are failing to meet these goals. A recent report from the Office of Inspector General, which reviewed 30 phase 3 trials funded by The National Institutes of Health, revealed that only two-thirds had inclusive enrollment plans. Even among those with such plans, most did not achieve their targets for underrepresented groups. To extend trial participation, many are looking towards scalable, comprehensive decentralized clinical trial solutions that enhance participant engagement and alleviate site burden. By building patient-centric diversified clinical trials, pharma can ensure more representative data, improve the efficacy and safety of treatments across different populations, and ultimately enhance health outcomes for all patients. https://lnkd.in/g-e4gGvM I #DecentralizedClinicalTrials #ClinicalTrialDiversity #DigitalClinicalTrials #HealthEquity PharmaVoice

NIH-funded trials fall flat on diversity goals

NIH-funded trials fall flat on diversity goals

pharmavoice.com

To view or add a comment, sign in

Explore topics